UroGen Pharma Ltd. (URGN)
| Market Cap | 1.17B |
| Revenue (ttm) | 109.79M |
| Net Income (ttm) | -153.49M |
| Shares Out | 48.71M |
| EPS (ttm) | -3.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 498,060 |
| Open | 23.85 |
| Previous Close | 23.77 |
| Day's Range | 22.61 - 24.58 |
| 52-Week Range | 3.42 - 30.00 |
| Beta | 1.44 |
| Analysts | Strong Buy |
| Price Target | 29.29 (+21.43%) |
| Earnings Date | May 11, 2026 |
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal... [Read more]
Financial Performance
In 2025, UroGen Pharma's revenue was $109.79 million, an increase of 21.45% compared to the previous year's $90.40 million. Losses were -$153.49 million, 21.0% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price target is $29.29, which is an increase of 21.43% from the latest price.
News
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen Pha...
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 results and a permanent J-code have accelerated adoption and revenue, with ZUSDURI now outpacing JELMYTO in key metrics. Debt refinancing enhances flexibility for R&D, while pipeline assets like UGN-103 and UGN-501 are advancing toward major milestones.
UroGen Pharma Earnings Call Transcript: Q4 2025
ZUSDURI's launch drove a 21% revenue increase in 2025, with accelerated adoption after a permanent J-code and strong pipeline progress. Financial flexibility improved with a $250 million refinancing, while JELMYTO continued steady growth.
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales...
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Fe...
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci...
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
RTGel enables sustained drug delivery for urothelial cancers, with ZUSDURI recently approved for a large bladder cancer market. Early launch shows strong revenue growth and physician enthusiasm, with ZUSDURI positioned as a non-surgical, chemoablative option and billion-dollar potential.
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci...
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing its innovative RTGel-based therapies for urothelial cancers, with ZUSDURI recently approved as the first non-surgical option for intermediate-risk NMIBC. Market adoption is expected to accelerate in 2025 with the introduction of a permanent J-code, while next-generation products and strong IP protection support long-term growth.
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci...
UroGen Pharma Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
RTGel technology enables extended drug delivery for urologic cancers, with Zusduri recently launched for intermediate-risk NMIBC. Early adoption is strong, with significant revenue growth and robust demand. Reimbursement improvements and a strong pipeline, including UGM-103 and an oncolytic virus, support long-term growth.
UroGen Pharma Earnings Call Transcript: Q3 2025
ZUSDURI launch is gaining momentum with strong physician interest and growing patient enrollment, though operational and reimbursement hurdles are delaying broader adoption until the permanent J code takes effect in 2026. JELMYTO continues to deliver steady revenue growth and remains a standard of care.
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the U...
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci...
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference
RTGel technology enables non-surgical, office-based therapies for urothelial cancers, with Zosduri recently FDA-approved for a large patient population. Early launch shows strong physician enthusiasm, robust demand, and broad market access. Pipeline includes next-gen products and immunotherapy, with solid cash reserves supporting growth.
UroGen Pharma Transcript: Cantor Global Healthcare Conference 2025
RTGel technology underpins two key products: Jelmyto, a kidney-sparing therapy for upper tract urothelial cancer, and Zosduri, a primary therapy for intermediate-risk NMIBC with strong clinical results. Zosduri targets a $5B+ market, with broad adoption expected after J-code implementation and a robust commercial infrastructure in place.